Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.

Property Value
dbo:abstract
  • Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-06-20 07:12:19Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 33052103 (xsd:integer)
dbo:wikiPageLength
  • 2474 (xsd:integer)
dbo:wikiPageModified
  • 2018-11-09 09:17:59Z (xsd:date)
dbo:wikiPageOutDegree
  • 6 (xsd:integer)
dbo:wikiPageRevisionID
  • 867996970 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)
rdfs:label
  • Vatelizumab (en)
owl:sameAs
foaf:isPrimaryTopicOf
is foaf:primaryTopic of